



HAL
open science

The intestinal virome: lessons from animal models

Lorenzo Chaffringeon, Quentin Lamy-Besnier, Laurent Debarbieux, Luisa de Sordi

► **To cite this version:**

Lorenzo Chaffringeon, Quentin Lamy-Besnier, Laurent Debarbieux, Luisa de Sordi. The intestinal virome: lessons from animal models. *Current Opinion in Virology*, 2021, 51, pp.141-148. 10.1016/j.coviro.2021.09.016 . hal-03541397

HAL Id: hal-03541397

<https://hal.sorbonne-universite.fr/hal-03541397v1>

Submitted on 24 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Long title: The intestinal virome: lessons from animal models**

2 **Short title: The virome of animal models**

3

4 **Authors**

5 Lorenzo Chaffringeon^{1,2,3}, Quentin Lamy-Besnier^{2,4}, Laurent Debarbieux², and Luisa De
6 Sordi^{1,3*}

7

8 **Affiliations**

9 1 Sorbonne Université, INSERM, Centre de Recherche St Antoine, UMRS_938, Paris, France

10 2 Department of Microbiology, Institut Pasteur, Paris F-75015 France.

11 3 Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, Paris, France.

12 4 Université de Paris, Paris, France

13

14 *** Correspondence**

15 luisa.de_sordi@sorbonne-universite.fr

16

17

18

19

20

21

22

23

24

25 **Abstract:**

26 Mucosal surfaces in contact with the environment host specific microbiota. The intestinal tract
27 harbours the most abundant and diverse bacterial and viral populations interacting with each
28 other as well as with the host. Viruses of the microbiota are important components of this
29 ecosystem, as shown by viral alterations associated with various pathologies. However,
30 practical and ethical constraints limit functional studies of the virome in humans, making
31 animal models invaluable experimental tools to understand its impact on intestinal
32 physiology. In this review, we present the recent advances in the study of virome in animal
33 models. We focus on the strategies used to characterise viral changes in disease models and
34 approaches to modulate the microbiota using viruses. In reviewing the interplay between
35 viruses, bacteria, and the animal host, we highlight the potential and limitations of these
36 models in elucidating the role of the virome in determining human health and disease.

37

38

39

40

41

42

43

44

45

46

47

48

49 **Introduction**

50 Several organs and mucosal membranes of animals are colonised by symbiotic microbes,
51 known as microbiota, which include bacteria, archaea, fungi, protozoa and viruses [1]. Viruses
52 of the microbiota are highly diverse and infect either eukaryotic or prokaryotic cells as obligate
53 parasites. Although viruses have mostly been studied as pathogens, they can establish a
54 mutualistic symbiosis with infected cells. This is well illustrated with bacteriophages (phages),
55 viruses that infect bacteria, the most abundant viruses in the microbiota. Their life cycle is
56 often either virulent, leading to phage replication and bacterial death, or temperate,
57 conferring a possible fitness advantage, acting as mobile genetic elements.

58 Differently from cellular organisms, the genetic information of viruses is stored in DNA or RNA,
59 single or double-stranded, and lacks common genetic markers, considerably limiting their
60 study. Shotgun metagenomics partially overcomes these limitations by being able to access
61 genomic information of different nature and is currently the gold-standard approach to study
62 many microbial environments [2]. Although virome analysis is still challenging, bioinformatics
63 tools are rapidly improving. Indeed, several studies have associated variations in virome
64 composition with human disease, raising questions about their underlying mechanisms. Most
65 have focused on intestinal phages and their overall impact on the bacteriome and gut
66 physiology [3], whereas a few have also examined eukaryotic viruses, which appear to play
67 similar roles as bacteria, affecting the development of host physiology and immunity [4].

68 Pre-clinical approaches using animal models present several advantages (ethics, costs, and
69 reproducibility) in preliminary investigations on the role of the virome in host physiology and
70 disease. In this review, we present and discuss the most recent advances in the
71 characterisation of the virome in animal models, the factors involved in its variation, its

72 mechanisms of interaction with the host, and the possible clinical and therapeutic
73 consequences, with a focus on phages.

74 **The intestinal virome of laboratory mice**

75 The use of mice as robust models of virome-associated disorders requires that the baseline
76 viral composition is known and comparable to that observed in clinical studies. Professional
77 providers of laboratory mice raise them under specific pathogen-free (SPF) conditions, which
78 implies that they are only screened for the absence of certain eukaryotic viruses. A major
79 difference in the virome of laboratory mice compared to wild ones is indeed the much lower
80 abundance of eukaryotic viruses, a factor that should be taken into account when discussing
81 the outcome of functional microbiome studies [5].

82 To date, no facilities control for the presence of phages, as they are *generally recognised as*
83 *safe* (GRAS) for animals, including humans. The composition of intestinal phages reflects the
84 composition of the intestinal bacteria, which varies between animal facilities and mouse lines.
85 Recent studies have consistently showed that most phages in SPF mice belong to the
86 *Microviridae* family (from 1-10 to 60-85%, depending on the mouse supplier) and Caudovirales
87 order (1-10 to 80-99%), whereas a minority are still unknown or unclassified (1-10 to 25%) [5–
88 7].

89 These results are coherent with observations in humans, in whom phages, *Microviridae* and
90 Caudovirales, are the major viral component of the intestinal microbiota relative to eukaryotic
91 viruses, as reviewed extensively elsewhere [8,9], further justifying the use of mice in pre-
92 clinical research. Also, certain phage taxa are consistently found in mice from the same
93 vendor, suggesting the existence of a core virome specific to breeding facilities [6].

94 However, the lack of common standards in virome extraction, sequencing and analysis makes
95 it hard to compare the high variability in composition observed in these studies. Sources of
96 differences include the nature of the starting material (intestinal content [6], faeces [7] or
97 caecal content[5]), the filtration method, the nucleic acid extraction (DNA and RNA viruses [5]
98 or DNA viruses only [6,7]) the sequencing technology (Illumina [5,6] or Ion Torrent [7]).
99 Increasing cycles of DNA amplification during the preparation of Illumina sequencing libraries,
100 was also shown to enrich single-stranded viral DNA, which is consistent with the variability
101 found in the proportion of *Microviridae* [2].

102 Overall, the impact of the virome on most animal studies is still unclear. It is possible that
103 experimental reproducibility within and between laboratories could be perturbed by
104 differences in the composition of the virome, as already shown for the bacterial microbiota
105 [10,11]. Exploring virome diversity in these studies would have the double function of
106 improving experimental practice and our understanding of the impact of viruses on host
107 physiology.

108 **The influence of diet on the animal virome**

109 The diet is a source of microbiome variability [12] and a major parameter of several widely
110 used models, such as those employing high-fat (HFD) and low-fat diets (LFD) to study diseases
111 such as obesity or type-2 diabetes. Thus, the effect of diet on the virome is of particular
112 interest.

113 After dietary intervention with a HFD or LFD, a study of six mice showed no significant
114 differences in the composition of the core faecal virome [6] but a significant change in the
115 alpha diversity (box 1) of phage populations. The bacteria, however, did not vary in alpha
116 diversity in caecal samples after 13 weeks, although the different taxonomic level of analysis

117 (strains vs genera) prevents a direct comparison between the viral and the bacterial
118 component. [6]. However, Schulfer *et al.* obtained different results for the faeces of 24 mice,
119 16 weeks after transitioning to a HFD, showing a non-significant increase in alpha diversity of
120 the viral community but a significant reduction in that of the bacterial population [7]. In terms
121 of beta diversity (box 1), there was a significant shift after transitioning to a HFD from a
122 standard diet (SD) in both the bacterial and viral populations in both studies [6,7]. A drop in
123 the ratio of temperate to virulent phages was also observed in mice transitioning to a HFD [7].
124 The results of these studies are consistent concerning HFD-related changes in the relative
125 abundance of phage, showing an increase in *Microviridae* [6,7] and a decrease in Caudovirales,
126 especially *Siphoviridae*, relative to a LFD [7].

127 The virome of mice is not only affected by diet but is also altered in several pathological
128 conditions. Moreover, in certain diseases, such as diabetes, the microbiota is a key factor in
129 the development of the pathology [13]. Although current evidence suggests a connection
130 between the microbiota and disease, the role of the virome in this context is still unknown.

131 **Models of disease and their impact on the virome**

132 Mice are often used as a proxy for human diseases to decipher their pathophysiology or test
133 new therapeutics. Virome diversity correlates with several pathological conditions, such as
134 inflammatory bowel disease [14], arthritis [15], and even child growth impairment [16].

135 In a mouse model, neurotoxic chemicals were administered to induce symptoms of Gulf War
136 illness, a chronic multisystemic disorder characterised by inflammatory bowel disease and
137 neuroinflammation, among other conditions. The authors observed significant changes in the
138 richness and composition of the virome associated with neuroinflammation driven by a
139 decrease in the levels of the proteins which ensure epithelial cell-cell junctions in the gut and

140 blood brain barrier. Additional antibiotic treatment did not significantly affect these
141 differences but a wide-spectrum anti-viral agent partially reversed them to a level similar to
142 that of the healthy control group [17]. Overall, these results suggest a role of the virome in
143 neuroinflammation and thus in the “gut-brain” axis [17,18].

144 In another mouse model, Cao *et al.* examined the effect of vaccination with the full-length
145 spike protein on the virome of mice infected with SARS-CoV2. Metagenomics analysis showed
146 a significant increase in alpha diversity in the virome of vaccinated mice relative to controls,
147 without evidence of viral infection in the gastrointestinal tract, suggesting either an
148 undetectable infection or modulation of the immune landscape that altered the gut
149 microbiome [19].

150 Given the known involvement of the virome in the physiopathology of diseases associated
151 with intestinal dysbiosis, the use of viruses to re-establish the microbial equilibrium has been
152 proposed. Strategies of faecal viral transfer have thus been developed in animal models.

153 **Modifying the microbiota of animal models in virome studies**

154 Faecal microbiota transplantation (FMT) and faecal viral transfer (FVT) (Figure 1) are used to
155 modify the gut microbiota of animal models, either to correct dysbiosis or to study the
156 resulting specific perturbations.

157 A HFD induces glucose intolerance and weight gain in mice [20]. These symptoms are
158 significantly reduced after FVT from LFD mice. However, depleting gut bacteria with antibiotics
159 neutralises the efficacy of FVT treatment, suggesting a crucial role for the gut bacteria of the
160 recipient in the success of FVT in controlling the symptoms of diabetes [20].

161 Mice fed a standard diet (SD) and treated by FMT or FVT from mice fed a HFD for 30 days had
162 a significantly different bacterial composition in the small intestine than untreated mice and
163 a beta diversity of bacteria comparable to that of mice fed a HFD. This shows that FMT and
164 FVT can specifically shift the gut microbiota towards the donor composition with similar
165 efficacy [21].

166 Thus, the effect of FVT depends on both the recipient and the donor [21], thus the choice of
167 donors is of utmost importance [22]. As mentioned previously, the composition of the murine
168 virome is highly variable depending on environmental factors, such as the vendors or diet.
169 Differences in the transferred material (faecal or caecal) also lead to grafting different viral
170 populations. To minimise these factors in animal studies, mixing caecal contents or faeces of
171 mice from different origins has been proposed [7,20].

172 The FVT can also originate from the recipient itself. Autochthonous FVT was shown to restore
173 the antibiotic-treated microbiota of mice to a closer composition to that of the pre-antibiotic
174 status relative to heat-inactivated FVT and increased the ratio between the bacterial phyla
175 *Bacteroidetes* and *Firmicutes*, which was lowered by the antibiotic treatment [23].

176 FVT can be an effective tool to modulate the microbiota. However, this raises the question of
177 which viruses are necessary or sufficient for the therapeutic action of FVT.

178 **Mechanisms underlying interactions with the virome**

179 The virome, bacteriome, and animal host coexist. Animal models reunite all three actors of
180 this tripartite interaction and allow its study in a controlled environment by separating the
181 myriad of parameters affecting its development (Figure 2).

182 ***Virome-host interactions***

183 The virome can affect the host by infecting it or by stimulating its immune system, either
184 directly or *via* the bacteriome. Animal models offer the possibility to study the mechanisms
185 behind such interactions. The advantages include the possibility of using genetic engineering
186 to decipher the molecular mechanisms at play *in vivo* [24] and measuring gene expression of
187 various host cells by RNA sequencing [19].

188 Phages can also interact directly with the mammalian host. Sweere *et al.* found that a
189 temperate filamentous phage of *Pseudomonas aeruginosa* can impair the murine immune
190 system in a wound-infection model by activating the TLR3 pathway and inhibiting the
191 production of TNF and phagocytosis, thus facilitating infection by its bacterial host [24]. In
192 addition, phages infecting the genera *Lactobacillus*, *Escherichia*, and *Bacteroides*, as well as
193 the phage DNA, triggered a specific inflammatory response in dendritic cells by stimulating
194 the INF γ response via TLR9 and exacerbated the inflammation in a DSS-induced colitis in wild-
195 type but not IFN γ ^{-/-} or TLR9^{-/-} mice [25]. A recent article demonstrated that a prophage
196 integrated into *Enterococcus hirae* interacts with the class I major histocompatibility complex
197 and enhances the efficacy of anti-tumour immune treatment in mice bearing this bacteria,
198 confirming the hypothesis resulting from metagenomic studies in human patients with a
199 differential response to treatment [26]. Overall, these studies show that the prokaryotic
200 virome can directly interact with the host immune system. [24,26].

201 ***Virome-bacteria interactions***

202 The interactions between phages and bacteria *in vivo* have already been reviewed [27–30].
203 Here, we will focus on a few examples that illustrate the value of animal models in these
204 studies.

205 Phages can directly modulate the gut microbiota by infecting their bacterial hosts, as well as
206 indirectly, by modulating the diversity of bacterial populations. The addition of four phages,
207 specific to a set of bacteria, profoundly shaped the microbiota of a gnotobiotic mouse model
208 composed of 10 bacterial strains (either phage-hosts or not) coupled with shifts in secreted
209 bacterial metabolites [31].

210 The host can affect both the virome and the bacteriome. Lourenço *et al.* demonstrated that
211 the spatial heterogeneity of the gut creates refuges that protect bacteria against phage
212 infection in a gnotobiotic mouse model [32]. However, Green *et al.* [33] showed that specific
213 phages can have a strong affinity for glycans, enhancing their effectiveness in the mucus layer.
214 Thus, phage-bacteria interactions vary greatly between phage studies depending on the
215 specificity of the phages, making it difficult to draw general conclusions.

216 De Sordi *et al.* characterised the phenomenon of “host jump” (change of host) occurring in the
217 murine gut. In this study, the diversity of the microbiota favoured the selection of genetic
218 modifications that allowed phage infection of an originally resistant host strain *via* adaptation
219 to intermediate intestinal hosts. This study shows the importance of the complexity of the
220 environment in phage-bacteria interactions that can be modelled in animals [34].

221 Conversely, bacteria can modulate the virome. Depletion of the bacterial community with
222 antibiotics in a rhesus monkey model was shown to reduce the alpha diversity and altered the
223 virome composition of both phages and eukaryotic viruses (box 2). The authors proposed a
224 mechanism in which metabolites produced by the bacteria could shift, inhibit, or promote
225 replication of the viruses [35].

226 Most of this work relies on reductionist approaches using defined couples of phages and
227 bacteria that can be monitored within intestinal microbiota of different complexity. The
228 necessity of simple model is partly driven by the fact that predicting the bacterial hosts of gut
229 bacteriophages is a challenging task in natural communities. However, new advances in
230 experimental and computational approaches show promise in tackling these limitations. As an
231 example, meta3C, derived from the chromosome conformation capture method (3C), was
232 used in mice microbiomes to assign putative bacterial hosts to specific phages using the
233 physical proximity between their genomes [36].

234 Animal models offer the possibility to unravel the complex relationships in which each
235 population influences the other two. They reunite all three actors, viruses, bacteria, and the
236 host, and each can be specifically modified to aid in the deciphering of this tripartite
237 association (Figure 2). Models with a controlled microbiota, also called gnotobiotic models,
238 facilitate the study of the virome using a simpler, characterised microbial environment.

239 **Non mouse models**

240 Although mice are the most widely used laboratory animals, other mammals are also suitable
241 for the study of the intestinal microbiota. Macaques are genetically closely related to humans
242 and are therefore a pertinent model to study parameters that influence the human virome.
243 Cynomolgus macaques have recently been used to analyse the effect of aging on the gut
244 virome [37]. Aging is already known to have an effect on the bacteriome [38], however, the
245 consequences of aging on the composition of the virome are mostly unknown. The macaque
246 virome has been found to be dominated by phages and alpha diversity is not significantly
247 altered with aging. However, the viral species change with age, which was also shown to be
248 the case for the KEGG pathways present in the virome, suggesting a role for the virome in

249 regulating metabolism [37]. The bacteriome and virome thus appear to be linked and to evolve
250 together as the animals age.

251 Zhao *et al.* characterised the enteric virome of rhesus macaques with chronic diarrhoea [39].
252 They found the virome to be dominated by phages of the Caudovirales order and *Microviridae*
253 families, much like the intestinal virome of mice and humans, as also confirmed in a second
254 study [35]. They also used biogeographical analysis, to find that the rectal virome is similar to
255 the one of the colon but distinct to the virome of the ileum. A recent study also confirmed the
256 distinction in virome composition between the large and the small intestine in rhesus monkey
257 and pigs with a higher phage diversity in the lumen and predominance of eukaryotic viruses
258 predominate in mucosal samples [40]. Recently, the faecal, oral, blood, and skin virome of
259 laboratory rabbits were described leading to the identification of a novel polyomavirus [41].
260 Finally, swine models have also been used for virome studies. For example, FVT was shown to
261 protect preterm pigs against necrotising enterocolitis [42].

262 Overall, these results show that different animals have a similar virome structure, with the
263 presence of key eukaryotic viruses and quantitative domination by phages. However, further
264 and more detailed characterisation of the components is required for a better understanding
265 their differences and roles.

266 **Conclusions**

267 The virome has been increasingly linked to health and disease. Although animal models have
268 been spearheading new discoveries in this field, the study of their virome is still in its infancy.
269 As for humans, phages are the most abundant component of the animal virome and new
270 mechanisms of their physiological roles remain to be characterised in relation to their direct
271 effect on the host and indirect effect as a modulator of bacterial populations. Further studies,

272 taking advantage of the flexibility of animal models, are required to investigate the
273 interactions of the virome with both other elements of the microbiome and the host. In
274 addition, future research needs to tackle the issue of determining the active actors in the
275 microbiota in physiology and pathophysiology. The challenge lies in dissociating the actions of
276 viruses from those of bacteria and between individual viruses, with the objective of identifying
277 key players in human health.

278

279 **Acknowledgements**

280 LC is funded by a PhD fellowship from the Ministère de l'Enseignement Supérieur et de la
281 Recherche, France, Ecole Doctorale 394. QLB is funded by École Doctorale FIRE - Programme
282 Bettencourt. LD receives fundings from ANR-20-CE92-0048, and LDS receives fundings from
283 the Agence Nationale de la Recherche (ANR) and the Société Nationale Française de Gastro-
284 Entérologie (SNFGE). Figures were created with Biorender.com.

285

286 **References**

- 287 1. Matijašić M, Meštrović T, Paljetak HČ, Perić M, Barešić A, Verbanac D: **Gut Microbiota**
288 **beyond Bacteria-Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD.**
289 *Int J Mol Sci* 2020, **21**:E2668.
- 290 2. Marine R, McCarren C, Vorrasane V, Nasko D, Crowgey E, Polson SW, Wommack KE:
291 **Caught in the middle with multiple displacement amplification: the myth of pooling**
292 **for avoiding multiple displacement amplification bias in a metagenome.** *Microbiome*
293 2014, **2**:3.
- 294 3. Manrique P, Dills M, Young MJ: **The Human Gut Phage Community and Its Implications**
295 **for Health and Disease.** *Viruses* 2017, **9**:E141.
- 296 4. Kernbauer E, Ding Y, Cadwell K: **An enteric virus can replace the beneficial function of**
297 **commensal bacteria.** *Nature* 2014, **516**:94–98.
- 298 5. Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, McCulloch JA,
299 Anastasakis DG, Sarshad AA, Leonardi I, et al.: **Laboratory mice born to wild mice have**
300 **natural microbiota and model human immune responses.** *Science* 2019, **365**.

301 6. Rasmussen TS, de Vries L, Kot W, Hansen LH, Castro-Mejía JL, Vogensen FK, Hansen AK,
302 Nielsen DS: **Mouse Vendor Influence on the Bacterial and Viral Gut Composition**
303 **Exceeds the Effect of Diet.** *Viruses* 2019, **11**:E435.

304 • This study underlines the important influence of the origin of the mice on the virome
305 composition, which should be taken into account when conceiving animal studies.
306

307 7. Schulfer A, Santiago-Rodriguez TM, Ly M, Borin JM, Chopyk J, Blaser MJ, Pride DT: **Fecal**
308 **Viral Community Responses to High-Fat Diet in Mice.** *mSphere* [date unknown],
309 **5**:e00833-19.

310 • This article is a necessary step towards the comprehension of the fundamental parameters
311 related to diet influencing the virome composition.
312

313 8. Liang G, Bushman FD: **The human virome: assembly, composition and host**
314 **interactions.** *Nat Rev Microbiol* 2021, doi:10.1038/s41579-021-00536-5.

315 9. Sausset R, Petit MA, Gaboriau-Routhiau V, De Paepe M: **New insights into intestinal**
316 **phages.** *Mucosal Immunol* 2020, **13**:205–215.

317 10. Franklin CL, Ericsson AC: **Microbiota and reproducibility of rodent models.** *Lab Anim*
318 2017, **46**:114–122.

319 11. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y: **Host variables**
320 **confound gut microbiota studies of human disease.** *Nature* 2020, **587**:448–454.

321 12. Bisanz JE, Upadhyay V, Turnbaugh JA, Ly K, Turnbaugh PJ: **Meta-Analysis Reveals**
322 **Reproducible Gut Microbiome Alterations in Response to a High-Fat Diet.** *Cell Host*
323 *Microbe* 2019, **26**:265-272.e4.

324 13. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI: **Mechanisms underlying the**
325 **resistance to diet-induced obesity in germ-free mice.** *Proc Natl Acad Sci U S A* 2007,
326 **104**:979–984.

327 14. Clooney AG, Sutton TDS, Shkoporov AN, Holohan RK, Daly KM, O'Regan O, Ryan FJ,
328 Draper LA, Plevy SE, Ross RP, et al.: **Whole-Virome Analysis Sheds Light on Viral Dark**
329 **Matter in Inflammatory Bowel Disease.** *Cell Host Microbe* 2019, **26**:764-778.e5.

330 15. Mangalea MR, Paez-Espino D, Kieft K, Chatterjee A, Chriswell ME, Seifert JA, Feser ML,
331 Demoruelle MK, Sakatos A, Anantharaman K, et al.: **Individuals at risk for rheumatoid**
332 **arthritis harbor differential intestinal bacteriophage communities with distinct**
333 **metabolic potential.** *Cell Host Microbe* 2021, **29**:726-739.e5.

334 16. Khan Mirzaei M, Khan MAA, Ghosh P, Taranu ZE, Taguer M, Ru J, Chowdhury R, Kabir
335 MM, Deng L, Mondal D, et al.: **Bacteriophages Isolated from Stunted Children Can**
336 **Regulate Gut Bacterial Communities in an Age-Specific Manner.** *Cell Host Microbe*
337 2020, **27**:199-212.e5.

- 338 17. Seth RK, Maqsood R, Mondal A, Bose D, Kimono D, Holland LA, Janulewicz Lloyd P,
339 Klimas N, Horner RD, Sullivan K, et al.: **Gut DNA Virome Diversity and Its Association**
340 **with Host Bacteria Regulate Inflammatory Phenotype and Neuronal Immunotoxicity**
341 **in Experimental Gulf War Illness.** *Viruses* 2019, **11**:E968.
- 342 18. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M,
343 Codagnone MG, Cusotto S, Fulling C, Golubeva AV, et al.: **The Microbiota-Gut-Brain**
344 **Axis.** *Physiol Rev* 2019, **99**:1877–2013.
- 345 19. Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, et al.: **Integrated**
346 **gut virome and bacteriome dynamics in COVID-19 patients.** *Gut Microbes* 2021, **13**:1–
347 21.
- 348 20. Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, Hansen LH,
349 Vogensen FK, Hansen AK, Nielsen DS: **Faecal virome transplantation decreases**
350 **symptoms of type 2 diabetes and obesity in a murine model.** *Gut* 2020, **69**:2122–2130.
- 351 • This work is a well-designed study investigating the differences between FVT and FMT, and
352 their importance for the clinical outcome.
- 353
- 354 21. Lin DM, Koskella B, Ritz NL, Lin D, Carroll-Portillo A, Lin HC: **Transplanting Fecal Virus-**
355 **Like Particles Reduces High-Fat Diet-Induced Small Intestinal Bacterial Overgrowth in**
356 **Mice.** *Front Cell Infect Microbiol* 2019, **9**:348.
- 357 22. Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM: **The Super-Donor Phenomenon in**
358 **Fecal Microbiota Transplantation.** *Front Cell Infect Microbiol* 2019, **9**:2.
- 359 23. Draper LA, Ryan FJ, Dalmaso M, Casey PG, McCann A, Velayudhan V, Ross RP, Hill C:
360 **Autochthonous faecal viral transfer (FVT) impacts the murine microbiome after**
361 **antibiotic perturbation.** *BMC Biol* 2020, **18**:173.
- 362 • This article includes a novel temporal aspect to the study of microbiome with FVT
363 treatment allowing the study of the evolution of the microbiome after an FVT.
- 364
- 365 24. Sweere JM, Belleghem JDV, Ishak H, Bach MS, Popescu M, Sunkari V, Kaber G,
366 Manasherob R, Suh GA, Cao X, et al.: **Bacteriophage trigger antiviral immunity and**
367 **prevent clearance of bacterial infection.** *Science* 2019, **363**.
- 368 •• This article is a great example of a phage interacting directly with the animal host immune
369 system.
- 370
- 371 25. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong
372 MC, Ghazaryan A, Valentine JF, et al.: **Expansion of Bacteriophages Is Linked to**
373 **Aggravated Intestinal Inflammation and Colitis.** *Cell Host Microbe* 2019, **25**:285-
374 299.e8.
- 375 26. Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT,
376 Goubet A-G, et al.: **Cross-reactivity between tumor MHC class I-restricted antigens**
377 **and an enterococcal bacteriophage.** *Science* 2020, **369**:936–942.

- 378 • This work highlights the mechanisms behind the interactions between a phage and the
379 immune system, influencing the outcome of cancer treatments.
380
- 381 27. Guerin E, Hill C: **Shining Light on Human Gut Bacteriophages.** *Front Cell Infect Microbiol*
382 2020, **10**:481.
- 383 28. Blazanic M, Turner PE: **Community context matters for bacteria-phage ecology and**
384 **evolution.** *ISME J* 2021, doi:10.1038/s41396-021-01012-x.
- 385 29. Dahlman S, Avellaneda-Franco L, Barr JJ: **Phages to shape the gut microbiota?** *Curr*
386 *Opin Biotechnol* 2021, **68**:89–95.
- 387 30. Shkoporov AN, Hill C: **Bacteriophages of the Human Gut: The “Known Unknown” of**
388 **the Microbiome.** *Cell Host Microbe* 2019, **25**:195–209.
- 389 31. Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, Silver PA, Gerber GK: **Dynamic**
390 **Modulation of the Gut Microbiota and Metabolome by Bacteriophages in a Mouse**
391 **Model.** *Cell Host Microbe* 2019, **25**:803-814.e5.
- 392 32. Lourenço M, Chaffringeon L, Lamy-Besnier Q, Pédrón T, Campagne P, Eberl C, Bérard M,
393 Stecher B, Debarbieux L, De Sordi L: **The Spatial Heterogeneity of the Gut Limits**
394 **Predation and Fosters Coexistence of Bacteria and Bacteriophages.** *Cell Host Microbe*
395 2020, **28**:390-401.e5.
- 396 •• This well-designed work illustrates the difference between *in vitro* and *in vivo* dynamics of
397 phages and bacterial populations and highlights the importance of the spatial heterogeneity
398 of the gut in such interactions.
399
- 400 33. Green SI, Gu Liu C, Yu X, Gibson S, Salmen W, Rajan A, Carter HE, Clark JR, Song X,
401 Ramig RF, et al.: **Targeting of Mammalian Glycans Enhances Phage Predation in the**
402 **Gastrointestinal Tract.** *mBio* [date unknown], **12**:e03474-20.
- 403 34. De Sordi L, Khanna V, Debarbieux L: **The Gut Microbiota Facilitates Drifts in the**
404 **Genetic Diversity and Infectivity of Bacterial Viruses.** *Cell Host Microbe* 2017, **22**:801-
405 808.e3.
- 406 35. Li H, Li H, Wang J, Guo L, Fan H, Zheng H, Yang Z, Huang X, Chu M, Yang F, et al.: **The**
407 **altered gut virome community in rhesus monkeys is correlated with the gut bacterial**
408 **microbiome and associated metabolites.** *Virology* 2019, **16**:105.
- 409 36. Marbouty M, Baudry L, Cournac A, Koszul R: **Scaffolding bacterial genomes and**
410 **probing host-virus interactions in gut microbiome by proximity ligation (chromosome**
411 **capture) assay.** *Sci Adv* 2017, **3**:e1602105.
- 412 37. Tan X, Chai T, Duan J, Wu J, Zhang H, Li Y, Huang Y, Hu X, Zheng P, Song J, et al.:
413 **Dynamic changes occur in the DNA gut virome of female cynomolgus macaques**
414 **during aging.** *MicrobiologyOpen* 2021, **10**:e1186.

- 415 38. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R,
416 Franceschi C, et al.: **Through ageing, and beyond: gut microbiota and inflammatory**
417 **status in seniors and centenarians.** *PloS One* 2010, **5**:e10667.
- 418 39. Zhao G, Droit L, Gilbert MH, Schiro FR, Didier PJ, Si X, Paredes A, Handley SA, Virgin HW,
419 Bohm RP, et al.: **Virome biogeography in the lower gastrointestinal tract of rhesus**
420 **macaques with chronic diarrhea.** *Virology* 2019, **527**:77–88.
- 421 40. Shkoporov A, Stockdale S, Lavelle A, Kondova I, Hueston C, Upadrasta A, Khokhlova E,
422 Kamp I van der, Ouwering B, Draper L, et al.: **Viral biogeography of gastrointestinal**
423 **tract and parenchymal organs in two representative species of mammals.** 2021,
424 doi:10.21203/rs.3.rs-803286/v1.
- 425 41. Xiao Y, Wang H, Feng L, Pan J, Chen Z, Wang H, Yang S, Shen Q, Wang X, Shan T, et al.:
426 **Fecal, oral, blood and skin virome of laboratory rabbits.** *Arch Virol* 2020, **165**:2847–
427 2856.
- 428 42. Brunse A, Deng L, Pan X, Hui Y, Kot W, Nguyen DN, Secher JB-M, Nielsen DS, Thymann
429 T: **Fecal filtrate transfer protects against necrotizing enterocolitis in preterm pigs.**
430 *bioRxiv* 2020, doi:10.1101/2020.05.25.114751.
- 431 43. Rasmussen TS, Jakobsen RR, Castro-Mejía JL, Kot W, Thomsen AR, Vogensen FK, Nielsen
432 DS, Hansen AK: **Inter-vendor variance of enteric eukaryotic DNA viruses in specific**
433 **pathogen free C57BL/6N mice.** *Res Vet Sci* 2021, **136**:1–5.
- 434 44. Dallari S, Heaney T, Rosas-Villegas A, Neil JA, Wong S-Y, Brown JJ, Urbanek K, Herrmann
435 C, Depledge DP, Dermody TS, et al.: **Enteric viruses evoke broad host immune**
436 **responses resembling those elicited by the bacterial microbiome.** *Cell Host Microbe*
437 2021, **29**:1014-1029.e8.
- 438 45. Ingle H, Lee S, Ai T, Orvedahl A, Rodgers R, Zhao G, Sullender M, Peterson ST, Locke M,
439 Liu T-C, et al.: **Viral complementation of immunodeficiency confers protection against**
440 **enteric pathogens via interferon-λ.** *Nat Microbiol* 2019, **4**:1120–1128.
- 441 •• This article investigates with success the active element of an FVT and shows that only
442 one virus was sufficient for its effectiveness in conferring protection against norovirus and
443 rotavirus infections.
444
- 445 46. Neil JA, Matsuzawa-Ishimoto Y, Kernbauer-Hözl E, Schuster SL, Sota S, Venzon M,
446 Dallari S, Galvao Neto A, Hine A, Hudesman D, et al.: **IFN-I and IL-22 mediate protective**
447 **effects of intestinal viral infection.** *Nat Microbiol* 2019, **4**:1737–1749.
- 448 47. Cortez V, Boyd DF, Crawford JC, Sharp B, Livingston B, Rowe HM, Davis A, Alsallaq R,
449 Robinson CG, Vogel P, et al.: **Astrovirus infects actively secreting goblet cells and alters**
450 **the gut mucus barrier.** *Nat Commun* 2020, **11**:2097.
- 451 48. Kuss SK, Best GT, Etheredge CA, Pruijssers AJ, Frierson JM, Hooper LV, Dermody TS,
452 Pfeiffer JK: **Intestinal microbiota promote enteric virus replication and systemic**
453 **pathogenesis.** *Science* 2011, **334**:249–252.

- 454 49. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A,
455 Louie T, Martinelli LP, et al.: **Treating Clostridium difficile infection with fecal**
456 **microbiota transplantation**. *Clin Gastroenterol Hepatol Off Clin Pract J Am*
457 *Gastroenterol Assoc* 2011, **9**:1044–1049.
- 458 50. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L,
459 Tholey A, Fickenscher H, Seegert D, et al.: **Efficacy of Sterile Fecal Filtrate Transfer for**
460 **Treating Patients With Clostridium difficile Infection**. *Gastroenterology* 2017, **152**:799-
461 811.e7.
- 462 51. Ahern PP, Maloy KJ: **Understanding immune-microbiota interactions in the intestine**.
463 *Immunology* 2020, **159**:4–14.

464

465

466 **Boxes and Figure legends**

467 **Box 1: Definitions of viral diversities from virome data**

468 In ecology, **diversity** reflects the relative abundance of different species while the **richness**
469 represents the number of different species. Within a specific ecosystem, the diversity is
470 defined as **alpha diversity**, whereas **beta diversity** measures differences in diversity between
471 two or more ecosystems. For the microbiota, the local ecosystem is the intestinal tract of a
472 specific individual, therefore the alpha diversity represents the intra-individual diversity while
473 the beta diversity represents the inter-individual diversity.

474

475 **Box 2: Roles of the eukaryotic virome in animal models**

476 SPF mice have a low abundance of eukaryotic viruses. When detected, the most represented
477 are DNA viruses of families *Phycodnaviridae* and *Mimiviridae* [7,43] or the RNA viruses of the
478 *Astroviridae* family [5]. However, viral annotation might be a limiting step in these analysis

479 since two studies detected high amounts of giant *Mimiviridae* (with capsid of approximately
480 0.7 μ m in diameter) that should have been excluded by filtration at 0.45 and 0.22 μ m [7].
481 Like for phages, the proportions of intestinal eukaryotic viruses are impacted by the diet, as
482 shown by HFD-fed mice showing significant relative increase in the most abundant intestinal
483 families [7]. Eukaryotic viruses also do interact with the immune system of the host. Dallari *et*
484 *al.* systematically assessed the immune response to six viruses belonging to different enteric
485 families. The authors found that these viruses have an immunomodulatory properties
486 independent of their capacity to induce gastroenteritis [44]. In another study, an intestinal
487 murine astrovirus could confer protection from norovirus and rotavirus infections by
488 complementing the animal immunodeficiency via the stimulation of IFN- λ -mediated signalling
489 in epithelial cells [45]. Here, the authors identify the active viral component by metagenomic
490 comparison of active and inactive FVT in transferring protection to viral pathogens. Viral
491 immunomodulation can also alter the physiopathology of bacterial infections. Both murine
492 norovirus and astrovirus were shown to confer protection from to pathogenic *E. coli* in the
493 gastrointestinal tract [46,47]. Conversely, mice treated with antibiotics are less susceptible to
494 poliovirus infection, suggesting a facilitating role of bacteria in the infection process [48].
495 Eukaryotic viruses are less abundant than phages in the microbiota, but their influence on the
496 host and its immune system is major. Whether a connection exists between the immune
497 response elicited by eukaryotic viruses and the diversity of phage populations is still
498 unexplored territory.

499

500

501

502

503 **Figure 1: Faecal Microbial and Viral Transplantation.**

504 Faecal Microbial Transplantation (FMT) is the procedure used to transfer the faecal microbiota
505 of an individual to himself or to another individual. It is used to correct dysbiosis and has
506 proven to be effective to treat recurrent infections from *Clostridioides difficile* [49]. Faecal
507 Viral Transplantation (FVT) is a similar approach that includes an additional filtration step
508 during the preparatory procedure. This method is aimed at eliminating intestinal bacteria
509 while keeping only viruses and small molecules. It is sometimes also referred to as sterile
510 Faecal Filtrate Transfer (FFT). FVT can be exposed to UV treatment or heat shock to inactivate
511 viruses and determine if the effect of the FVT is due to viral activity or other small metabolites.
512 Conversely, the effect of small molecules can be eliminated by a supplementary filtration step
513 that will retain viral particles while excluding other small compounds. FVT has shown similar
514 efficacy as FMT in treating *C. difficile* infection in a small clinical assay with 5 patients [50]
515 while alleviating potential secondary effects such as the implantation of pathogenic bacteria.
516 FVT is used in animal models to decipher the importance of the virome in the mechanisms
517 governing physiology and pathology, as described in section “Modifying the microbiota of
518 animal models in virome studies”.

519

520 **Figure 2: Virome, bacteriome, host: three actors and a myriad of interactions**

521 Schematic representation of the interactions between the viral, the bacterial compartments
522 and the host. Most of the studies on the microbiota have focused on the bacteria-host
523 interactions as reviewed by Ahern and Maloy [51] (dashed arrow). Viruses (blue arrows) have
524 a strong connection to bacteria (green arrows): both populations regulate each other, directly
525 (e.g., by phage predation or mutualism) or indirectly (*via* the immune system of the host). In
526 turn, the virome can shift the metabolome by modulating bacterial populations and indirectly

527 impacting the barrier and immunity (production cytokine is shown as coloured circles) of the
528 host [31]. Antibiotic treatments can alter the alpha diversity of eukaryotic viruses,
529 demonstrating that bacteria can also affect the diversity of eukaryotic viruses. The host
530 (orange arrows), is interacting with eukaryotic and prokaryotic viruses that modulate its
531 immune landscape and the epithelial barrier. The host offers a particular environment for
532 phage-bacteria interactions and modulates their populations by secreting small regulatory
533 molecules or by its spatial heterogeneity affecting their interactions. All displayed connections
534 were drawn from studies in animal models, as described in this review.

535

536

537

538

539

540

541

542

543

544

545

546


547

548

549


550

551 **Figure1**



552

553 **Figure 2**



554

555